Point Of Care Infectious Disease Testing Market Demonstrates Long-Term Growth Potential At 13.5% CAGR

The point of care infectious disease testing market is poised for significant expansion as healthcare continues to embrace rapid, accessible diagnostic solutions. Driven by technological advancements and increasing demand for quick, reliable results outside traditional laboratory settings, this sector is set to transform how infectious diseases are detected and managed worldwide. Let's explore the market's projected growth, key players, emerging trends, and segment breakdowns shaping this evolving industry.

Strong Growth Forecast for the Point of Care Infectious Disease Testing Market
The market for point of care infectious disease testing is projected to grow swiftly, reaching a valuation of $9.02 billion by 2030. This represents a compound annual growth rate (CAGR) of 13.5%. Key factors fueling this expansion include rising adoption of self-testing kits, rapid development of molecular point of care diagnostics, increased investment in integrating digital health technologies, greater attention to outbreak readiness, and growing demand for affordable rapid testing options. Among the trends expected to shape the market are greater use of rapid molecular tests, increasing popularity of home-based testing, broader application of multiplex diagnostic kits, growth in portable diagnostic devices, and a heightened focus on early disease detection.

The point of care infectious disease testing market size has grown rapidly in recent years. It will grow from $4.78 billion in 2025 to $5.44 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to rising incidence of infectious diseases, increased demand for rapid diagnostics, expansion of decentralized healthcare delivery, availability of lateral flow testing technologies, growing use of rapid screening in hospitals.

Download a free sample of the point of care infectious disease testing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24382&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Organizations Driving the Point of Care Infectious Disease Testing Market
The market is dominated by several prominent companies, including Cardinal Health, F Hoffmann La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton dic*kinson and Company, bioMérieux Société Anonyme, QuidelOrtho Corporation, Bio Rad Laboratories Inc., DiaSorin Società per Azioni, Danaher Corporation, Cue Health Inc., Nova Biomedical Corporation, Seegene Incorporated, Biosynex Société Anonyme, Trivitron Healthcare Private Limited, EKF Diagnostics Holdings plc, Trinity Biotech Public Limited Company, bioLytical Laboratories Inc., Cepheid Inc., LumiraDx UK Ltd., Meridian Bioscience Inc., and GenBody Inc.

A notable development in July 2024 saw Switzerland-based pharmaceutical giant F. Hoffmann-La Roche AG acquire LumiraDx's point of care technology for $295 million. This strategic move aims to broaden global access to decentralized diagnostic testing by integrating LumiraDx's flexible point-of-care platform into Roche's diagnostics range. LumiraDx, a US medical equipment manufacturer specializing in infectious disease testing, provides tools that enable prompt and actionable results, particularly benefiting primary care and underserved healthcare environments.

View the full point of care infectious disease testing market report:
https://www.thebusinessresearchcompany.com/report/point-of-care-infectious-disease-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Technological Innovations Transforming the Point of Care Infectious Disease Testing Market
Industry leaders are focusing on incorporating cutting-edge technologies, such as proprietary microfluidic systems, to enhance the precision, speed, and overall performance of point of care tests. Microfluidic technology involves manipulating tiny fluid volumes on a microscale to enable swift, accurate, and affordable diagnostics. This approach facilitates on-site pathogen detection with integrated sample processing and result delivery, reducing reliance on centralized labs.

A prime example of this innovation occurred in June 2023, when Japan's Sysmex Corporation launched the PA-100 AST System in Europe. This device is the world's first point-of-care solution capable of directly assessing antimicrobial susceptibility. Using advanced microfluidics, it rapidly identifies bacterial infections and evaluates the effectiveness of antimicrobial treatments, significantly shortening turnaround times compared to traditional methods. The compact, desktop analyzer operates with single-use cartridges, making it ideal for near-patient environments like primary care clinics. By enabling faster and more accurate decisions about antimicrobial therapy, the system supports global efforts to combat antimicrobial resistance through improved diagnostic efficiency.

Detailed Market Segmentation of the Point of Care Infectious Disease Testing Industry
This report categorizes the point of care infectious disease testing market into several key segments:

1) Product Type: Kits and Reagents, Instruments
2) Technology: Lateral Flow Immunoassay, Agglutination Test, Flow-through Test or Immunoconcentration Assay, Molecular Diagnostics, Other Technologies
3) Disease Application: Human Immunodeficiency Virus (HIV) Point-of-Care Testing, Clostridium Difficile Testing, Hepatitis B Virus Testing, Pneumonia or Streptococcus-related Infections, Respiratory Syncytial Virus Testing, Human Papillomavirus Testing, Influenza (Flu) Testing, and Other Diseases
4) End Use: Hospitals, Diagnostic Centers, Research and Academic Institutes, Homecare Settings, Other End Users

Further subcategories refine these segments: within Kits and Reagents, there are Test Kits and Reagents; Instruments are divided into Portable Devices and Automated Analyzers. This detailed segmentation provides a comprehensive overview of the products, technologies, diseases addressed, and customer types driving the market forward.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.